アリゾナ州における多発性骨髄腫の臨床試験
アリゾナ州内の拠点で、多発性骨髄腫に関する28件の研究が参加者を募集しています。
アリゾナ州内の都市
公式研究テキスト（英語）
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- City of Hope Phoenix, Goodyear
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07589634Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Arizona, Scottsdale
被験者募集中
18歳以上 · 全性別 · 2026/10/01更新 · NCT06630104A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gilbert
- Research Site, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic 1, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Phoenix, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
- University of Arizona Cancer Center, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05201781A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Mayo Clinic Hospital Scottsdale /ID# 278349, Scottsdale
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Phoenix, Phoenix
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Hospital in Arizona, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT06375044A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Bullhead City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Cancer Center at Saint Joseph's, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Phoenix
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Gilbert
- Research Site, Phoenix
- Research Site, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Banner MD Anderson Cancer Center, Gilbert
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Arizona, Phoenix
- HonorHealth, Scottsdale
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Arizona - Phoenix, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/16更新 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona /ID# 251405, Phoenix
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Cancer Center at Saint Joseph's, Phoenix
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Arizona, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT03017820Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Banner University Medical Center Tucson, University of Arizona, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Banner MD Anderson, Gilbert
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06433947A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Arizona Oncology Associates, Tucson
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT05972135A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- CTCA at Western Regional Medical Center, Goodyear
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/02/20更新 · NCT07225738ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。